Sarepta Therapeutics (SRPT) Earnings Analysis
Sarepta Therapeutics (SRPT) has no confirmed upcoming earnings date. Last quarter (2025-11-03) it missed with EPS -0.13 USD vs 0.01 USD est (-1400%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E 25.52.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SRPT next report earnings?
No confirmed upcoming earnings date is currently scheduled for SRPT. This page updates as the calendar is published.
SRPT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-11-03 | -0.13 USD | 0.01 USD | -1400% | Miss |
| 2025-02-26 | 1.5 USD | 1.38 USD | +8.7% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
SRPT valuation and analyst view
| Trailing P/E | 25.52 |
|---|---|
| Trailing EPS | 0.61966 USD |
| Price / book | 1.10 |
| Dividend yield | 0.00% |
| Market cap | 1.68B |
| Analyst consensus | Buy (31 buy / 18 hold / 6 sell) |
| Avg price target | 22 USD |
Related research pages
Frequently asked questions
When is Sarepta Therapeutics (SRPT)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for SRPT. This page updates as the calendar is published.
Did SRPT beat earnings last quarter?
In its 2025-11-03 report, SRPT posted EPS of -0.13 USD versus a 0.01 USD estimate — a miss of 1400%.
What is SRPT's earnings track record?
Over the last 2 reported quarters with consensus data, SRPT beat estimates 1 times (50%).
What is SRPT's current P/E ratio and EPS?
SRPT trades at a trailing P/E of 25.52 on trailing EPS of 0.6196612946241475 USD.
What do analysts rate SRPT?
Analyst consensus is "Buy" across 55 ratings (0 strong buy, 31 buy, 18 hold, 6 sell, 0 strong sell). Average 12-month price target: 22 USD.